RxDoctor Payments Data
★ My doctorsLook up a doctor →

Kenneth Rivlin

Pediatric Hematology-Oncology · New York, NYNPI 1245202662

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,608 of the $2,372 with a category attached, or 67.8%. CSL Behring accounts for 83.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $1,973 and has fallen 93.7% since, to $125 in 2025.

$2,372in general payments, 2019–2025

Across 10 payments — averaging $237.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$2K
  • Pfizer$250
  • Novo Nordisk$125
  • Novartis$25
$528,612in research payments, 2019–2025

Across 262 payments — averaging $2017.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Global Blood Therapeutics, Inc.$305K
  • Novartis$114K
  • Pfizer$49K
  • CSL Behring$47K
  • Novo Nordisk AS$14K

What the payments were for

  • Consulting fees$25011%
  • Travel & lodging$1,60868%
  • Food & beverage$51522%

General payments by program year

19
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
CSL Behring7$1,973
Pfizer1$250
Novo Nordisk1$125
Novartis1$25

How this compares

$2,372 in reported general payments places this provider in the 65th percentile of 196 pediatric hematology-oncology providers in New York.

See all pediatric hematology-oncology providers in New York →

Other pediatric hematology-oncology in New York

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →